Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.53 |
| ▸ | BCL2 | P10415 | 15/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687647 | 1.00 | BCL2L1 (0.53) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL26683013 | 0.93 | BCL2L1 (0.54) | BCL2L1BCL2MCL1 | |
| SCHEMBL26681627 | 0.92 | BCL2L1 (0.54) | BCL2L1BCL2MCL1AURKAPLK1 | |
| SCHEMBL26681922 | 0.91 | BCL2L1 (0.54) | BCL2L1BCL2MCL1 | |
| SCHEMBL26681464 | 0.91 | BCL2L1 (0.51) | BCL2L1BCL2MCL1 | |
| SCHEMBL30687726 | 0.91 | BCL2L1 (0.48) | BCL2L1BCL2MCL1 | |
| SCHEMBL26681966 | 0.91 | BCL2L1 (0.48) | BCL2L1BCL2MCL1 | |
| SCHEMBL30687584 | 0.90 | BCL2L1 (0.42) | BCL2L1BCL2MCL1MGLL | |
| SCHEMBL26680753 | 0.90 | BCL2L1 (0.42) | BCL2L1BCL2MCL1MGLL | |
| SCHEMBL30687886 | 0.90 | BCL2L1 (0.67) | BCL2L1BCL2MCL1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | BCL2L1 650/4885BCL2 131/4885MCL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.